US FDA Withholds Approval for Injectafer Due to Manufacturing Facility Issues: Daiichi Sankyo

July 30, 2012
Daiichi Sankyo announced on July 26 that its US subsidiary Luitpold Pharmaceuticals, Inc. has received a Complete Response Letter from the US FDA for the treatment of iron deficiency anemia Injectafer (ferric carboxymaltose injection) for which a new drug application...read more